Tag - AYTU

Markets

Cantor starts Aytu BioPharma at OW; PT $11

Cantor Fitzgerald launched coverage of Aytu BioPharma (NASDAQ:AYTU) with an “overweight” rating and $11 price target. The stock closed at $7.49 on March 29. “Through a strategy of in-licensing and acquisition-based...

March 29, 2021

Markets

Mackie ups Acerus Pharma PT to 50 cents from 40 cents

Mackie Research raised its price target for Acerus Pharmaceuticals (TSX:ASP, OTCQB:ASPCF) to 50 cents from 40 cents, reflecting an amended agreement with Aytu Biosciences (NASDAQ:AYTU) that would move their partnership...

July 31, 2019

Tag - AYTU

Cantor starts Aytu BioPharma at OW; PT $11

Mackie ups Acerus Pharma PT to 50 cents from 40 cents

General

More